Navigation Links
Mayo Clinic and ReachMD Launch “Updates from Mayo Clinic” Featuring Expert Interviews and Panel Discussions on Mental Health in Pediatric Primary Care
Date:5/31/2013

Fort Washington, PA (PRWEB) May 31, 2013

ReachMD, an award-winning producer and nationwide distributor of healthcare information and education for medical professionals, announced today its collaboration with Mayo Clinic on a new series titled Updates from Mayo Clinic. Hosted by Dr. Peter S. Jensen, Professor of Psychiatry and Vice Chair for Research at Mayo Clinic in Rochester, Minnesota, the series launches with a focus on recent advances in the management of psychiatric and neurologic disorders in the pediatric population.

Each broadcast segment is 15 minutes and features host Dr. Jensen with renowned guests from academic centers, medical institutions, and societies. The series broadcasts on air on XM Satellite Radio Channel 245, is simulcast online on ReachMD.com, and can be downloaded on demand through the free MedicalRadio™ app available on iTunes.

"We are pleased to launch this Series in collaboration with ReachMD to capture insights from medical experts across the country in the constantly evolving realm of psychiatric and neurologic disorders,” said Dr. Jensen, host of the series.

Dr. Jensen’s interviews span a spectrum of mental health management issues in pediatric primary care, including:

  • Limiting Overprescribing vs Underprescribing of ADHD Medicati
    '/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. FDA Review in Journal for ImmunoTherapy of Cancer Offers New Insights into Cancer Immunotherapy Product Development & Clinical Evaluation
2. Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
3. Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks
4. Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches
5. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials
7. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
8. Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
9. Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)
10. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
11. Computational Analysis in Clinical and Preclinical Decision-Making, new webinar hosted by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
... relatively spherical objects in a sauce blueberries in ... of completely encapsulated berries. Relying on that concept, ... in protective coatings in the belief such encapsulations would ... Unfortunately, reactions in the nanoworld are not logical extensions ...
... On October 10, the web domain "GenerationHealth.com" was listed for auction ... expected to deliver a price reminiscent of the early dot-com days. ... expected to garner a lot of attention due to the fact ... frequently lately for various reasons, and also because the domain can ...
... AZ, Oct. 12 /PRNewswire/ - Dynamic Ventures Corporation ... Editorial Board of Standard and Poor,s ("S&P") has ... Market Access Program. Standard & Poor,s Corporation Records ... U.S. and international public companies by investors and ...
Cached Biology Technology:Nanoscopic particles resist full encapsulation, Sandia simulations show 2Dynamic Ventures Corporation's Information To Be Available Through Standard & Poor's Market Access Program 2
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... Bacteria that can cause serious heart disease in humans are ... could become a bigger problem in humans. Research published in ... suggests that brown rats, the biggest and most common ... Since the early 1990s, more than 20 species of ...
... kills pain by activating a set of proteins ... appetite, inflammation, and memory. The body also has ... same receptors, namely N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol ... remain the focus of intense efforts to develop ...
... Nov. 21 Futronic Technology Company Limited, a,global ... the,commercial release of FS22, a high performance fingerprint ... its previously launched,FS21M (mid-range device) and FS20 (low ... fingerprint access and attendance control device.,FS22 uses a ...
Cached Biology News:Scientists discover 21st century plague 2Scripps research team defines new painkilling chemical pathway 2Futronic Launches FS22 Fingerprint Access Control Device 2